Amman, June 5 (Petra)– The U.S. Supreme Court has ruled that Hikma
Pharmaceuticals’ generic version of the cardiovascular drug Vascepa
does not infringe patents held by Amarin Pharma, in a landmark
decision that could reduce the exposure of generic drug manufacturers
to patent litigation involving so-called “skinny labels.”

The ruling represents a significant achievement for Hikma
Pharmaceuticals, one of Jordan’s leading pharmaceutical companies,
underscoring its strong competitive position in global markets and
its ability to successfully navigate complex legal disputes with
major international drugmakers.

The decision is also considered a major victory for the generic
pharmaceutical industry, as it strengthens manufacturers’ ability to
introduce lower-cost alternatives to brand-name medicines while
reducing legal risks associated with patent infringement claims.

According to Reuters, the unanimous 9-0 decision, authored by Justice
Ketanji Brown Jackson, overturned a lower court ruling that had
favored Amarin Pharma.

Legal experts say the judgment could limit future patent infringement
lawsuits tied to “skinny labels,” a regulatory mechanism that allows
generic drugmakers to market medicines for approved uses that are not
covered by existing patents while excluding patented indications from
product labeling.

Generic drug manufacturers had warned that a ruling in Amarin’s favor
could have discouraged the development and marketing of lower-cost
medicines, potentially contributing to higher drug prices in the
United States.

The Supreme Court’s decision is expected to provide greater legal
certainty for generic pharmaceutical companies and reinforce
competition in the U.S. healthcare market, helping expand access to
affordable treatments for patients.

//Petra// MF